|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
|
AU2012233313C1
(en)
*
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
|
TWI687439B
(zh)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
RU2014117505A
(ru)
*
|
2011-09-30 |
2015-11-10 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула для ускорения удаления антигенов
|
|
TW201817744A
(zh)
*
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
EP2752200B1
(en)
|
2011-09-30 |
2023-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
|
JP6322411B2
(ja)
*
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
KR20230143201A
(ko)
|
2011-11-30 |
2023-10-11 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
MX360352B
(es)
|
2012-02-15 |
2018-10-30 |
Hoffmann La Roche |
Cromatografia de afinidad basada en receptores fc.
|
|
EP3738980A1
(en)
|
2012-02-24 |
2020-11-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib
|
|
EP3539374A1
(en)
|
2012-03-16 |
2019-09-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
EP2825036B1
(en)
|
2012-03-16 |
2018-05-02 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
KR20150008082A
(ko)
*
|
2012-04-27 |
2015-01-21 |
바이오아트라, 엘엘씨 |
수정된 항체 영역 및 그의 용도
|
|
WO2013180200A1
(ja)
*
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
|
EP2857419B1
(en)
*
|
2012-05-30 |
2021-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
|
SG10201709559PA
(en)
|
2012-08-24 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
|
GB201302878D0
(en)
*
|
2013-02-19 |
2013-04-03 |
Argen X Bv |
Modified igG molecules
|
|
CN105246914B
(zh)
|
2013-04-02 |
2021-08-27 |
中外制药株式会社 |
Fc区变体
|
|
UA118029C2
(uk)
|
2013-04-29 |
2018-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
|
|
WO2014177459A2
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
MX2016003617A
(es)
|
2013-09-30 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
|
|
KR102813659B1
(ko)
|
2013-11-11 |
2025-05-28 |
추가이 세이야쿠 가부시키가이샤 |
개변된 항체 가변영역을 포함하는 항원 결합 분자
|
|
DK3078744T3
(da)
|
2013-12-04 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
|
|
MX380658B
(es)
|
2014-01-15 |
2025-03-11 |
Hoffmann La Roche |
Variantes de region fc con union mejorada de la proteina a.
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
CN106103478B
(zh)
|
2014-03-21 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
抗体体内半寿期的体外预测
|
|
ES2869459T3
(es)
*
|
2014-05-16 |
2021-10-25 |
Medimmune Llc |
Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
|
|
KR20170015920A
(ko)
*
|
2014-06-12 |
2017-02-10 |
에프. 호프만-라 로슈 아게 |
ＦｃＲｎ 상호작용이 변화된 항체를 선별하는 방법
|
|
FR3024453B1
(fr)
*
|
2014-08-01 |
2018-06-29 |
Lab Francais Du Fractionnement |
Procede de production de variants ayant un fc presentant une sialylation amelioree
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CA2960569A1
(en)
*
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-Laroche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
|
EP3215175A4
(en)
*
|
2014-11-06 |
2018-06-27 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
|
TWI831044B
(zh)
|
2014-11-11 |
2024-02-01 |
日商中外製藥股份有限公司 |
抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
BR112017011235A2
(pt)
|
2014-12-19 |
2018-02-06 |
Chugai Pharmaceutical Co Ltd |
anticorpos anti-c5 e métodos de uso
|
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
US9879080B2
(en)
|
2015-01-28 |
2018-01-30 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
US10464999B2
(en)
|
2015-01-28 |
2019-11-05 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
US10633433B2
(en)
|
2015-01-28 |
2020-04-28 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
CA2972393A1
(en)
|
2015-02-27 |
2016-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating il-6-related diseases
|
|
HRP20211081T1
(hr)
|
2015-09-15 |
2021-10-15 |
Scholar Rock, Inc. |
Anti-pro/latentna miostatinska protutijela i njihove uporabe
|
|
UA120981C2
(uk)
*
|
2015-09-18 |
2020-03-10 |
Чугаі Сейяку Кабусікі Кайся |
Антитіло, що зв'язується з il-8, та його застосування
|
|
AR107078A1
(es)
|
2015-12-18 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
CN115814077A
(zh)
|
2016-01-08 |
2023-03-21 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
|
|
CA3011887C
(en)
*
|
2016-03-14 |
2024-10-29 |
Universitetet I Oslo |
Genetically transformed immunoglobulins with altered FCRN binding
|
|
CA3024618A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
EP4628094A3
(en)
*
|
2016-06-06 |
2025-12-31 |
City of Hope |
BAFF-R ANTIBODIES AND THEIR USES
|
|
CN116769024A
(zh)
|
2016-06-14 |
2023-09-19 |
瑞泽恩制药公司 |
抗c5抗体及其用途
|
|
KR102376582B1
(ko)
|
2016-06-17 |
2022-03-18 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체 및 사용 방법
|
|
HRP20260151T1
(hr)
*
|
2016-08-02 |
2026-03-27 |
Visterra, Inc. |
Modificirani polipeptidi i njihova uporaba
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
|
|
WO2018031258A1
(en)
*
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
EP4218817A3
(en)
|
2017-01-06 |
2023-09-06 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
|
JP6974500B2
(ja)
*
|
2017-01-13 |
2021-12-01 |
ハンクス バイオファーマシューティクス，インコーポレイテッド |
ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
|
KR102365871B1
(ko)
|
2017-01-31 |
2022-02-21 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
|
EP3580233A1
(en)
*
|
2017-02-10 |
2019-12-18 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
CN110506055A
(zh)
|
2017-02-17 |
2019-11-26 |
戴纳立制药公司 |
工程改造的转铁蛋白受体结合多肽
|
|
CA3120566C
(en)
|
2017-04-07 |
2023-12-12 |
Kookmin University Industry Academy Cooperation Foundation |
Antibody fc variants for increased blood half-life
|
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
KR20200014379A
(ko)
*
|
2017-06-05 |
2020-02-10 |
얀센 바이오테크 인코포레이티드 |
비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
DK3658184T5
(da)
|
2017-07-27 |
2024-08-26 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
|
US11059892B2
(en)
|
2017-08-11 |
2021-07-13 |
Research Development Foundation |
Engineered antibody Fc variants for enhanced serum half life
|
|
AU2018345807B2
(en)
|
2017-10-06 |
2025-02-06 |
Novo Nordisk A/S |
Methods of detecting transthyretin
|
|
CU24731B1
(es)
|
2017-10-06 |
2025-01-15 |
Prothena Biosciences Ltd |
Anticuerpos anti-transtiretina
|
|
EP3699590A4
(en)
*
|
2017-10-20 |
2021-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF MEASURING THE INTERNALIZATION OF A MOLECULE IN A CELL
|
|
CN118512588A
(zh)
|
2017-10-26 |
2024-08-20 |
亚力兄制药公司 |
用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
|
|
PE20210119A1
(es)
|
2017-10-31 |
2021-01-19 |
Staten Biotechnology B V |
Anticuerpos anti-apoc3 y metodos de uso de estos
|
|
EP4640703A3
(en)
|
2017-11-14 |
2026-04-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
PE20211453A1
(es)
|
2017-11-29 |
2021-08-05 |
Prothena Biosciences Ltd |
Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
|
|
TW201938194A
(zh)
|
2017-12-05 |
2019-10-01 |
日商中外製藥股份有限公司 |
包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
|
|
CA3274059A1
(en)
|
2017-12-13 |
2026-03-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibody combinations and uses thereof
|
|
WO2019152413A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Oncoimmune, Inc. |
Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
|
|
KR102834864B1
(ko)
|
2018-02-02 |
2025-07-16 |
온코씨4, 아이앤씨. |
개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
|
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
|
IL314733A
(en)
*
|
2018-03-26 |
2024-10-01 |
Regeneron Pharma |
Humanized rodents for testing therapeutic agents
|
|
AU2019247511B2
(en)
|
2018-04-06 |
2025-10-16 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
EP3774892A4
(en)
*
|
2018-04-13 |
2022-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
AU2019269361C1
(en)
|
2018-05-14 |
2025-06-12 |
Children's Research Institute, Children's National Medical Center |
Anti-CD24 compositions and uses thereof
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
EP3802603A1
(en)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
GB201809341D0
(en)
|
2018-06-07 |
2018-07-25 |
Ucb Biopharma Sprl |
Multi-domain proteins with increased native state colloidal stability
|
|
TWI857959B
(zh)
|
2018-06-26 |
2024-10-11 |
日商協和麒麟股份有限公司 |
與細胞黏著分子3 結合之抗體
|
|
JP7397444B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
コンドロイチン硫酸プロテオグリカン－５に結合する抗体
|
|
US12312394B2
(en)
|
2018-06-28 |
2025-05-27 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-C5 antibodies
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
|
MY210523A
(en)
|
2018-08-01 |
2025-09-29 |
Univ Osaka |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
|
KR102259473B1
(ko)
|
2018-08-10 |
2021-06-02 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
|
AU2019359475A1
(en)
|
2018-10-12 |
2021-05-20 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
|
|
EP3873602B1
(en)
|
2018-10-30 |
2023-12-06 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
|
|
JP7410143B2
(ja)
*
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
AR117453A1
(es)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
Fc de anticuerpos modificados y métodos para utilizarlas
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE WITH ANTIGEN-BINDING DOMAIN WITH VARIABLE BINDING ACTIVITY TO ANTIGEN DEPENDING ON MTA AND LIBRARY TO OBTAIN THE ANTIGEN-BINDING DOMAIN
|
|
US20220213140A1
(en)
|
2019-04-10 |
2022-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying fc region-modified antibody
|
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
|
CN114007643A
(zh)
*
|
2019-04-19 |
2022-02-01 |
中外制药株式会社 |
识别抗体改变部位的嵌合受体
|
|
EP4696320A2
(en)
|
2019-05-15 |
2026-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibody
|
|
AU2020287378A1
(en)
*
|
2019-06-06 |
2022-02-03 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
CA3142735A1
(en)
*
|
2019-06-06 |
2020-12-10 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
AU2020289477A1
(en)
*
|
2019-06-07 |
2022-02-03 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
US20220288219A1
(en)
*
|
2019-07-08 |
2022-09-15 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
MX2022001286A
(es)
*
|
2019-07-30 |
2022-07-19 |
Mythic Therapeutics Inc |
Construcciones de proteínas de unión a antígenos y usos de estas.
|
|
AU2020330307A1
(en)
*
|
2019-08-12 |
2022-03-17 |
CSL Innovation Pty Ltd |
Complement C2 binding proteins and uses thereof
|
|
CA3156803A1
(en)
|
2019-10-03 |
2021-04-08 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
EP4037775A1
(en)
*
|
2019-10-04 |
2022-08-10 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021087462A1
(en)
*
|
2019-10-31 |
2021-05-06 |
The Research Foundation For The State University Of New York |
Rage antibodies, fragments and uses thereof
|
|
AU2020403913B2
(en)
|
2019-12-18 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific anti-CCL2 antibodies
|
|
UA128549C2
(uk)
|
2019-12-27 |
2024-08-07 |
Чугаі Сейяку Кабусікі Кайся |
Антитіло до ctla-4 та його застосування
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
JP7634545B2
(ja)
*
|
2020-01-29 |
2025-02-21 |
コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション |
ｐＨ感応性ＦＣ変異体
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
EP4133269A1
(en)
*
|
2020-04-08 |
2023-02-15 |
F. Hoffmann-La Roche AG |
Large molecule unspecific clearance assay
|
|
WO2022044248A1
(ja)
|
2020-08-28 |
2022-03-03 |
中外製薬株式会社 |
ヘテロ二量体Ｆｃポリペプチド
|
|
CA3173944A1
(en)
|
2021-01-13 |
2022-07-21 |
Visterra, Inc. |
Humanized complement 5a receptor 1 antibodies and methods of use thereof
|
|
RS66266B1
(sr)
|
2021-02-03 |
2024-12-31 |
Mythic Therapeutics Inc |
Anti-met antitela i njihova primena
|
|
AU2022295067A1
(en)
|
2021-06-18 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
AR126220A1
(es)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
TWI879694B
(zh)
|
2021-06-25 |
2025-04-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CN115572331A
(zh)
*
|
2021-07-06 |
2023-01-06 |
联邦生物科技(珠海横琴)有限公司 |
一种具有增强FcRn受体结合的突变子
|
|
EP4387994A4
(en)
*
|
2021-08-20 |
2025-07-02 |
Univ New York State Res Found |
IGA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION
|
|
KR20250122541A
(ko)
|
2022-10-25 |
2025-08-13 |
사이즈믹 테라퓨틱, 인코포레이티드. |
변이체 IgG FC 폴리펩티드 및 그 용도
|
|
EP4638496A1
(en)
|
2022-12-22 |
2025-10-29 |
Scholar Rock, Inc. |
Selective and potent inhibitory antibodies of myostatin activation
|
|
AU2024242538A1
(en)
*
|
2023-03-24 |
2025-10-30 |
Paragon Therapeutics, Inc. |
Fc fragments that bind fcrn and methods of use
|
|
US12286475B2
(en)
|
2023-07-31 |
2025-04-29 |
Sanofi |
Anti-GPRC5D antibodies and compositions
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
WO2025260124A1
(en)
*
|
2024-06-17 |
2025-12-26 |
CSL Innovation Pty Ltd |
MULTIFUNCTIONAL FcRn ANTAGONISTS AND USES THEREOF
|
|
FR3167160A1
(fr)
|
2024-10-08 |
2026-04-10 |
Alga Biologics |
Immunoglobulines avec affinite augmentee pour le fcrn
|
|
CN120365429B
(zh)
*
|
2025-06-30 |
2025-09-05 |
上海交通大学医学院附属仁济医院 |
Cd70特异性纳米抗体、分子影像探针及其制备方法和应用
|